A deadly hantavirus outbreak linked to a cruise ship has sparked a wave of conspiracy theories online, reviving COVID-era vaccine skepticism and fueling false claims about pharmaceutical companies and ...

Moderna's MRNA.O mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A deadly hantavirus outbreak linked to a cruise ship has sparked a wave ...

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Messenger RNA technology, or mRNA, is widely ...

May 6 (Reuters) - Moderna's (MRNA.O), opens new tab mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and ...

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Subscribe to read this story ad-free Get ...

Moderna shares briefly spiked Thursday morning as news unfolded over a cluster of hantavirus cases that originated among passengers traveling last month on a Dutch-flagged cruise from Argentina to ...

After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals has now decided to discontinue the program entirely. Vertex initially paused ...

Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 consensus on $17.56B in revenue while its non-COVID portfolio grew 9% operationally, led by Abrysvo (+136%) and Lorbrena (+45%), plus a ...

Moderna MRNA-0.77%decrease; red down pointing triangle reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets. The vaccine maker on ...

CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s return to prosperity. After a tussle with the FDA earlier this year over the ...